Peripheral blood free DNA extraction method
By optimizing the composition and reaction conditions of lysate, magnetic beads and washing solution, the problem of low extraction efficiency and purity of free DNA in the blood is solved, efficient extraction and enrichment is achieved, pollution is reduced, and it is suitable for clinical testing and suitable for domestic environment. Promotion.
Patent Information
- Application Number
- CN202411432888.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-15
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art is difficult to effectively extract and enrich free DNA with low content in the blood, and there is a problem of contaminated fragments, which affects the accuracy of gene detection and research progress.
Using a peripheral blood free DNA extraction method, by adjusting the composition and reaction conditions of lysate, magnetic beads and washing solution, combined with the use of protease K, the extraction steps are optimized to improve the efficiency and purity of nucleic acid extraction, including the use of lysate 1 and lysate Liquid 2 is digested twice, and the amino-silicon-sylated magnetic beads are used for efficient adsorption, and DNA stability and adsorption are promoted through appropriate salt and anhydrous ethanol environment.
It significantly improves the extraction rate of free DNA in peripheral blood, reduces large fragment pollution, increases the extraction rate by more than 50%, and the quality of the DNA products obtained is higher, suitable for clinical testing, low price, and suitable for domestic environmental promotion.
Smart Images

Figure CN119020352A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to a method for extracting free DNA from peripheral blood. Background Art
[0002] Plasma DNA, also known as blood circulating DNA and free DNA, refers to the DNA that is free outside the cells in the blood. Its sources are mainly three: DNA released by the disintegration of white blood cells, DNA released into the blood by necrotic tissue, especially tumor tissue, and DNA infected by viruses and bacteria.
[0003] In recent years, with the development of genetic diagnosis technology, the application value of free DNA has become increasingly greater, such as eugenics screening, early diagnosis of tumors, genetic disease detection and pathogen infection gene detection. However, the content of free DNA in the blood is generally low, the fragments are small, and it is not easy to extract, which greatly affects the genetic detection of free nucleic acids and the development of various studies.
[0004] The methods for extracting free DNA generally include the Trizol method, the centrifugal column method, and the magnetic bead method. Among them, the magnetic bead method is more suitable for machine automated extraction, but the nucleic acid extraction rate of the magnetic bead method is not as good as that of the centrifugal column method and the Trizol method. If the amount of free nucleic acid to be extracted is relatively low, it is best to choose the centrifugal column method.
[0005] How to improve the extraction rate of free DNA, reduce the generation of contaminating fragments, and achieve efficient and stable extraction and enrichment of samples with low content or relatively precious samples is the focus of research in this field. Summary of the invention
[0006] The first aspect of the present invention provides a method for extracting free DNA from peripheral blood, comprising:
[0007] S1. Place a certain amount of plasma into a centrifuge tube containing 100 μL to 150 μL of proteinase K, add 100 μL to 150 μL of lysis solution 1, mix well, and react at 15-60°C for 10-60 minutes to obtain a mixed solution;
[0008] S2. Add 4 mL to 8 mL of lysate 2 and 30 μL to 50 μL of magnetic beads to the mixed solution obtained in S1, mix well at room temperature, and react for 10-60 minutes; transfer to a magnetic rack after centrifugation, let stand to adsorb the magnetic beads, and discard the solution;
[0009] S3. Add 0.5 mL to 0.8 mL of washing solution 1, mix well, centrifuge, place on a magnetic stand for adsorption, and discard the solution;
[0010] S4. Add 0.5 mL to 0.8 mL of washing solution 2, mix well, transfer to a magnetic stand for adsorption, and discard the solution;
[0011] S5. After centrifugation, remove all residual liquid and dry the magnetic beads in air for 2 to 5 minutes;
[0012] S6. Add 50 μL to 100 μL of elution buffer, transfer the DNA to a magnetic rack for adsorption after it is fully dissolved, and transfer the supernatant containing cfDNA to a new centrifuge tube to obtain the cfDNA extraction product;
[0013] Wherein, the amount of plasma in step S1 is 0.5-4 mL, preferably 2 mL.
[0014] Lysis buffer 1 contains 0.05% to 1% sodium citrate dodecahydrate and 1% to 5% SDS;
[0015] Lysis solution 2 contains 10% to 20% guanidine thiocyanate, 1% to 5% NP40, 3% potassium chloride, 2% sodium chloride, 0.1% to 0.3% sodium dihydrogen phosphate, 0.5% to 1% tris(hydroxymethyl)aminomethane, 0.05% to 0.2% sodium tartrate and 25% isopropanol.
[0016] Preferably, the components of lysate 1 are 0.07% sodium citrate dodecahydrate and 4% SDS.
[0017] Preferably, the lysis solution 2 further comprises 2% to 10% of sodium lauroylamino acid.
[0018] More preferably, the components of lysate 2 are 20% guanidine thiocyanate, 3% NP40, 3% potassium chloride, 2% sodium chloride, 4% sodium lauroyl amino acid, 0.1% sodium dihydrogen phosphate, 0.7% tris(hydroxymethyl)aminomethane), 0.05% sodium tartrate and 25% isopropanol.
[0019] Preferably, the magnetic beads are amino-siliconized magnetic beads. More preferably, the magnetic beads are amino-siliconized magnetic beads with a solid content of 1% to 5%.
[0020] Preferably, the washing solution 1 contains 20% to 25% guanidine thiocyanate, 0.2% to 1% SDS, and 30% to 50% anhydrous ethanol.
[0021] Preferably, the washing solution 2 contains 0.1% to 0.8% tris(hydroxymethyl)aminomethane, 0.5% to 1% Trinton X-100, and 70% to 80% anhydrous ethanol.
[0022] More preferably, the washing solution 1 further comprises 0.2% to 0.5% of tris(hydroxymethyl)aminomethane and 1.5% to 5% of potassium chloride.
[0023] Preferably, the eluent contains 0.05% to 0.2% of tris(hydroxymethyl)aminomethane.
[0024] The second aspect of the present invention provides a kit for extracting free DNA from peripheral blood, comprising the above-mentioned lysis solution 1 and lysis solution 2.
[0025] Preferably, the kit for extracting free DNA from peripheral blood further comprises the above-mentioned washing solution 1, washing solution 2, and elution solution.
[0026] The third aspect of the present invention provides the use of the above-mentioned lysis solution 1 and lysis solution 2 in the preparation of a medical device for extracting free DNA from peripheral blood. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 Showing the difference in area under the main peak of cfDNA fragment distribution detected by capillary electrophoresis.
[0028] Figure 2 The difference in the main peak position of cfDNA fragment distribution detected by capillary electrophoresis is shown.
[0029] Figure 3 Capillary electrophoresis was used to detect the differences in large fragment interference peaks in the distribution of cfDNA fragments. DETAILED DESCRIPTION
[0030] In order to obtain DNA products that meet subsequent detection standards under different clinical collection methods and improve the extraction efficiency and quality of free DNA in human peripheral blood, the present invention systematically adjusts and combines reagents such as lysate, magnetic beads, washing solution, reaction conditions, and operating steps used in the extraction process.
[0031] The method for extracting free DNA from peripheral blood provided by the present invention first uses lysis solution 1 (mainly composed of SDS component) to denature the protein in serum plasma, thereby improving the effect of the second digestion of the sample by lysis solution 2 (mainly composed of guanidine isothiocyanate component), while also reducing the nonspecific adsorption of protein macromolecules to magnetic beads, which is beneficial to improving the yield and purity of nucleic acid.
[0032] In view of the problem that different anticoagulant blood collection tubes have different degrees of influence on the quality of plasma nucleic acid, the present invention compares different chelating agents and concentrations such as sodium tartrate, sodium gluconate and EDTA. Preferably, 0.05% to 0.2% sodium tartrate is added to the lysate 2 to achieve compatibility with different types of blood collection tubes.
[0033] Furthermore, 25% isopropanol was added to the lysis solution 2 to improve the stability of the nucleic acid fragments and reduce degradation. The salt environment for nucleic acid lysis was optimized by adjusting the concentration ratio of sodium chloride and potassium chloride.
[0034] Commonly used nucleic acid binding magnetic beads are mainly amino magnetic beads, carboxyl magnetic beads, siliconized magnetic beads and amino-siliconized magnetic beads, depending on the type of surface modification. In view of the characteristics of fragmented and trace free DNA in human peripheral blood, the present invention comprehensively screens the types and concentrations of magnetic beads, and preferably amino-siliconized magnetic beads with a solid content of 1% to 5%, because they can more stably and efficiently bind cfDNA, including methylated cfDNA, and have high adsorption efficiency.
[0035] An environment with appropriate concentrations of salt, anhydrous ethanol and isopropanol is conducive to promoting the adsorption of cfDNA onto magnetic beads, while an appropriate concentration of proteinase K can promote complete digestion of proteins.
[0036] The effect of washing solution 1 focuses on removing impurities such as protein, sugar and isopropanol. Washing solution 2 can further remove salt impurities.
[0037] By selecting, optimizing the combination, and adjusting the concentration ratio of the above reagents, they work together in the extraction process, thereby greatly improving the efficiency and quality of peripheral blood free DNA nucleic acid extraction. Compared with expensive foreign commercial extraction kits, the extraction method provided by the present invention improves the extraction rate by more than 50%, reduces the occurrence of large fragment contamination during the extraction process, and is low in price, suitable for domestic environments, easy to promote, and has high application value.
[0038] The present invention is further illustrated by examples, and the following examples are only used to explain the present invention and should not be construed as limiting the scope of the present invention. Unless otherwise specified, the technical and scientific terms used herein are the meanings generally understood by those of ordinary skill in the art to which the present invention belongs. If no specific conditions are specified in the examples, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be obtained commercially.
[0039] As used herein, the term "comprising" is synonymous with "including". As used herein, the terms "comprising", "including", "having", "containing" or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a composition, process, method, article, or apparatus comprising the listed elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, process, method, article, or apparatus.
[0040] Example 1
[0041] The amount of each reagent used in the extraction process can be adaptively adjusted according to the amount of plasma and the proportion of plasma volume. The amount of plasma is preferably 0.5 to 4 mL. Taking the extraction of cfDNA from 2 mL of plasma as an example, the present invention specifically includes the following steps:
[0042] 1. Place plasma in a centrifuge tube containing 100 μL to 150 μL of proteinase K, add 100 μL to 150 μL of lysis solution 1, mix well, react at 15-60°C for 10-60 minutes, for example, at 55°C for 30 minutes, to obtain a mixed solution.
[0043] The lysis solution 1 contains sodium dodecyl sulfate (SDS); preferably, the lysis solution 1 contains 0.05% to 1% sodium citrate dodecahydrate and 1% to 5% SDS.
[0044] In this embodiment, the components of the lysis solution 1 are 0.07% sodium citrate dodecahydrate and 4% SDS.
[0045] 2. Add 4 mL to 8 mL of lysate 2 and 30 μL to 50 μL of magnetic beads to the mixed solution obtained in step 1, mix well at room temperature (e.g., invert to mix well), react for 10-60 minutes, e.g., 10 minutes; transfer to a magnetic rack after centrifugation, let stand for 2-10 minutes to adsorb the magnetic beads, and discard the solution.
[0046] Lysis solution 2 comprises 10% to 20% guanidine thiocyanate, 1% to 5% alkoxypolyethylene hydroxyethanol (NP40), 3% potassium chloride, 2% sodium chloride, 0.5% to 1% tris(hydroxymethyl)aminomethane, 0.05% to 0.2% sodium tartrate and 25% isopropanol; preferably, lysate 2 comprises 20% guanidine thiocyanate, 3% NP40, 3% potassium chloride, 2% sodium chloride, 2% to 10% sodium lauroyl aminoacid, 0.1% to 0.3% sodium dihydrogen phosphate, 0.7% tris(hydroxymethyl)aminomethane, 0.05% sodium tartrate and 25% isopropanol.
[0047] In this embodiment, the components of lysate 2 are 20% guanidine thiocyanate, 3% NP40, 3% potassium chloride, 2% sodium chloride, 4% sodium lauroyl amino acid, 0.1 sodium dihydrogen phosphate, 0.7% tris(hydroxymethyl)aminomethane, 0.05% sodium tartrate and 25% isopropanol.
[0048] Preferably, the magnetic beads are amino-siliconized magnetic beads with a solid content of 1% to 5%. In this embodiment, the magnetic beads are 2.5% (w / v) silica amino magnetic beads (Silica Magnetic Beads (-NH2)). The present invention does not limit the dilution concentration of the magnetic beads in the reaction system when used. Those skilled in the art can dilute the magnetic bead stock solution according to actual conditions, for example, dilute it to 0.003%-0.01% magnetic bead suspension.
[0049] 3. Add 0.5 mL to 0.8 mL of washing solution 1, mix well (e.g., invert and mix well), centrifuge, place on a magnetic stand for adsorption for 1-3 minutes, e.g., 1 minute, and discard the solution. This step can be repeated 1-5 times according to actual needs.
[0050] The washing solution 1 contains 20% to 25% guanidine thiocyanate, 0.2% to 1% SDS and 30% to 50% anhydrous ethanol; preferably, the washing solution 1 contains 25% guanidine thiocyanate, 0.2% to 0.5% tris(hydroxymethyl)aminomethane, 1.5% to 5% potassium chloride, 0.5% SDS and 50% anhydrous ethanol.
[0051] In this embodiment, the components of the washing solution 1 are 25% guanidine thiocyanate, 0.3% tris(hydroxymethyl)aminomethane, 2% potassium chloride, 0.5% SDS and 50% anhydrous ethanol.
[0052] 4. Add 0.5 mL to 0.8 mL of washing solution 2, mix well (e.g. vortex for 5 seconds), transfer to the magnetic stand for adsorption for 1 minute, and discard the solution. Repeat this step 1-3 times according to actual needs.
[0053] The components of the washing liquid 2 are 0.1% to 0.8% of tris(hydroxymethyl)aminomethane, 0.5% to 1% of 4-(1,1,3,3-tetramethylbutyl)phenyl-polyethylene glycol, t-octylphenoxypolyethoxyethanol, polyethylene glycol tert-octylphenyl ether (Trinton X-100) and 70% to 80% of anhydrous ethanol.
[0054] In this embodiment, the components of the washing solution 2 are 0.3% tris(hydroxymethyl)aminomethane, 0.7% Trinton X-100, and 75% anhydrous ethanol.
[0055] 5. After centrifugation, aspirate the residual liquid; air dry the magnetic beads for 2 to 5 minutes, and avoid over-drying.
[0056] 6. Add 50 μL to 100 μL of elution buffer and shake at 37°C for 5 minutes to fully dissolve the DNA; transfer to a magnetic rack and adsorb for 1-3 minutes, transfer the supernatant containing cfDNA to a new centrifuge tube to obtain the cfDNA extraction product.
[0057] The eluent contained 0.05% to 0.2% tris(hydroxymethyl)aminomethane.
[0058] In this embodiment, the eluent is 0.1% tris(hydroxymethyl)aminomethane.
[0059] The concentration units of the above-mentioned lysate, washing solution and eluent components are mass percentages.
[0060] Comparative Example 1
[0061] The 16 plasma samples were extracted according to the peripheral blood free DNA extraction method in Example 1 to obtain extraction products, and according to the instructions of the commercial reagent VAHTS Free-Circulating DNA Maxi Kit (NWZ reagent) to obtain extraction products.
[0062] The components of the NWZ reagent include Proteinase K, VAHTS Particles G, Buffer L / B, Buffer WA, Buffer WB and Elution Buffer. Compared with the present method, the reagent has only one lysis buffer Buffer L / B. When in use, the lysis buffer Buffer L / B, magnetic beads VAHTS Particles G, proteinase K and the sample are directly mixed together to complete the lysis and free DNA adsorption process. The present invention comprises lysis buffer 1 and lysis buffer 2. Proteinase K and lysis buffer 1 are first used to perform preliminary lysis on the sample, and then lysis buffer 2 and magnetic beads are used to complete the complete lysis of the sample and the adsorption of free DNA.
[0063] The difference in Ct values when using β-actin gene detection reflects the content of nucleic acid template; Qubit4.0 was used to quantitatively determine the double-stranded DNA concentration of the extracted product, and the results are shown in Table 1.
[0064] Table 1
[0065]
[0066] The Ct values and concentration test results of samples 1-16 were summarized, and ΔCt and concentration ratio were calculated for the same sample, ΔCt = Ct value obtained by the method of Example 1 - Ct value obtained by the NWZ reagent method, concentration ratio = concentration obtained by the method of Example 1 / concentration obtained by the NWZ reagent method. The results showed that the Ct value of the product obtained by the method provided by the present invention was increased by 0.65 to 1.56, with an average increase of 1.06, and the concentration of the product obtained was 2.14 to 4.07 times that of the NWZ method, with an average of 2.65 times.
[0067] Capillary electrophoresis was performed using the Qsep100 fully automatic nucleic acid and protein analyzer to analyze the fragment size and distribution of the extracted products.
[0068] The results are as follows Figure 1 As shown, the extraction method of Example 1 also has a good extraction effect for extremely small amounts of nucleic acids in plasma ( Figure 1 Left); Under the same sample size, commercial kits are often unable to detect the main peak of cfDNA ( Figure 1 right).
[0069] The results are as follows Figure 2 As shown, the extraction method of Example 1 was used to obtain the main peak of the cfDNA extraction product at 160-175 bp ( Figure 2 Left), while the main peak of cfDNA extracted by commercial kit is 175-190bp ( Figure 2Right), indicating that the quality of cfDNA extracted by the method provided by the present invention is better and closer to the reference value of plasma free DNA fragment length of 167bp.
[0070] The results are as follows Figure 3 As shown, by using the extraction method of Example 1, the cfDNA extraction product obtained has less large fragment contamination ( Figure 3 Left), compared with commercial kits, the error caused by operation is smaller.
[0071] Comparative Example 2 Effect of the components and concentration of the lysate on the extraction effect
[0072] According to the extraction method in Example 1, only the components and concentration of the lysate were adjusted under the condition that the reaction conditions and operation procedures remained unchanged. The difference in Ct value when using β-actin gene detection reflected the content of nucleic acid template; Qubit4.0 was used to quantitatively determine the double-stranded DNA concentration of the extracted product. The results are shown in Table 2.
[0073] Table 2
[0074]
[0075] The results showed that only lysis buffer 1 or 2 could not improve the extraction efficiency. The combined effect of lysis buffer 1 and lysis buffer 2 could improve the extraction efficiency by 2 to 4 times.
[0076] While lysate 1 remained unchanged, the components and concentrations of lysate 2 were adjusted to obtain different combinations, as shown in Table 3.
[0077] Table 3
[0078]
[0079]
[0080] The test results are shown in Table 4.
[0081] Table 4
[0082]
[0083] Result explanation: Comparing the results of combination 1 and combination 3, it can be seen that sodium tartrate can promote the compatibility of the extraction reagent with different types of blood collection tubes.
[0084] Comparing the results of combination 3, combination 6, combination 7 and combination 8, it can be seen that the extraction efficiency of free DNA is best when the dosage of potassium chloride and sodium chloride is 3% and 2% respectively.
[0085] Comparing the results of combination 2, combination 3, combination 4 and combination 5, it can be seen that the extraction effect is best when the dosage of isopropanol is 25%.
[0086] Comparative Example 3 Effect of magnetic beads on extraction effect
[0087] According to the extraction method in Example 1, under the condition that the reagent components, concentrations, reaction conditions and operation procedures remain unchanged, only the magnetic beads are replaced with non-amino-siliconized magnetic beads, i.e., amino-type magnetic beads, carboxyl-type magnetic beads and silicon-type magnetic beads. The difference in Ct value when using β-actin gene detection reflects the content of nucleic acid template; the double-stranded DNA concentration of the extracted product is quantitatively determined using Qubit4.0. The results are shown in Table 5:
[0088] Table 5
[0089]
[0090] The results show that compared with carboxyl magnetic beads, silica-based magnetic beads and amino magnetic beads, amino-silica-based magnetic beads have a significant effect on improving the extraction rate.
[0091] The above specific implementations do not constitute a limitation on the protection scope of the present invention. It should be understood by those skilled in the art that various modifications, combinations, sub-combinations and substitutions can be made according to design requirements and other factors. Any modification, equivalent substitution and improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for extracting free DNA from peripheral blood, comprising: S1. Place 0.5-4 mL of plasma into a centrifuge tube containing 100 μL-150 μL of proteinase K, add 100 μL-150 μL of lysis solution 1, mix well, and react at 15-60°C for 10-60 minutes to obtain a mixed solution; S2. Add 4 mL to 8 mL of lysate 2 and 30 μL to 50 μL of magnetic beads to the mixed solution obtained in S1, mix well at room temperature, and react for 10-60 minutes; transfer to a magnetic rack after centrifugation, adsorb the magnetic beads, and discard the solution; S3. Add 0.5 mL to 0.8 mL of washing solution 1, mix well, centrifuge, place on a magnetic stand for adsorption, and discard the solution; S4. Add 0.5 mL to 0.8 mL of washing solution 2, mix well, transfer to a magnetic stand for adsorption, and discard the solution; S5. After centrifugation, remove all residual liquid and dry the magnetic beads in air for 2 to 5 minutes; S6. Add 50 μL to 100 μL of elution buffer, dissolve the DNA and transfer it to a magnetic rack for adsorption, transfer the supernatant containing cfDNA to a new centrifuge tube to obtain the cfDNA extraction product; Lysis buffer 1 contains 0.05% to 1% sodium citrate dodecahydrate and 1% to 5% SDS; Lysis solution 2 contains 10% to 20% guanidine thiocyanate, 1% to 5% NP40, 3% potassium chloride, 2% sodium chloride, 0.1% to 0.3% sodium dihydrogen phosphate, 0.5% to 1% tris(hydroxymethyl)aminomethane, 0.05% to 0.2% sodium tartrate and 25% isopropanol.
2. The method for extracting free DNA from peripheral blood according to claim 1, characterized in that: In step S1, the plasma volume is 2 mL; Lysis buffer 1 consisted of 0.07% sodium citrate dodecahydrate and 4% SDS; Lysis solution 2 also contains 2% to 10% of sodium lauroylamino acid.
3. The method for extracting free DNA from peripheral blood according to claim 1, characterized in that: The components of lysis solution 2 are 20% guanidine thiocyanate, 3% NP40, 3% potassium chloride, 2% sodium chloride, 4% sodium lauroyl amino acid, 0.1% sodium dihydrogen phosphate, 0.7% tris(hydroxymethyl)aminomethane, 0.05% sodium tartrate and 25% isopropanol.
4. The method for extracting free DNA from peripheral blood according to claim 1, characterized in that: The magnetic beads are amino-siliconized magnetic beads.
5. The method for extracting free DNA from peripheral blood according to claim 1, characterized in that: The washing solution 1 comprises 20% to 25% guanidine thiocyanate, 0.2% to 1% SDS, and 30% to 50% anhydrous ethanol; The washing solution 2 contains 0.1% to 0.8% tris(hydroxymethyl)aminomethane, 0.5% to 1% Trinton X-100, and 70% to 80% anhydrous ethanol.
6. The method for extracting free DNA from peripheral blood according to claim 1, characterized in that: The washing liquid 1 further contains 0.2% to 0.5% of tris(hydroxymethyl)aminomethane and 1.5% to 5% of potassium chloride.
7. The method for extracting free DNA from peripheral blood according to claim 1, characterized in that: The eluent contained 0.05% to 0.2% of tris(hydroxymethyl)aminomethane.
8. A kit for extracting free DNA from peripheral blood, comprising: The lysate 1 and lysate 2 according to any one of claims 1 to 3.
9. The kit for extracting free DNA from peripheral blood according to claim 8, characterized in that: It also includes the washing solution 1, washing solution 2, and eluent as described in any one of claims 5-7.
10. Use of the lysing solution 1 and the lysing solution 2 as described in any one of claims 1 to 3 in preparing a medical device for extracting free DNA from peripheral blood.
